Company intelligence / Profile preview

Verge Genomics

South San Francisco, California, United Statesvergegenomics.com ↗

Ownership: Private
Employees: ~200
Development stage: Phase 1

Overview

Verge Genomics has advanced its lead candidate VRG50635, a PIKfyve inhibitor for ALS treatment, into clinical trials. The company has demonstrated the ability to identify novel targets and develop them into clinical candidates using its AI platform.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

VRG50635

5 more assets in the full pipeline.

Request access →

Partnerships

Eli Lilly ($706 million partnership)Alexion/AstraZeneca Rare DiseaseFerrer

Beyond the preview

Go deeper on Verge Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verge Genomics.

Explore the full profile